$191.88 Million in Sales Expected for Omnicell, Inc. (OMCL) This Quarter
Analysts expect Omnicell, Inc. (NASDAQ:OMCL) to announce sales of $191.88 million for the current quarter, according to Zacks. Three analysts have made estimates for Omnicell’s earnings, with the highest sales estimate coming in at $192.19 million and the lowest estimate coming in at $191.60 million. Omnicell posted sales of $176.74 million during the same quarter last year, which suggests a positive year over year growth rate of 8.6%. The business is scheduled to issue its next quarterly earnings results on Thursday, October 26th.
According to Zacks, analysts expect that Omnicell will report full-year sales of $191.88 million for the current financial year, with estimates ranging from $728.80 million to $731.86 million. For the next fiscal year, analysts anticipate that the company will post sales of $813.20 million per share, with estimates ranging from $808.50 million to $818.50 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Omnicell.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.02. The firm had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same period last year, the company earned $0.38 earnings per share.
Several analysts have recently commented on the company. Benchmark Co. increased their price objective on Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reissued a “hold” rating and issued a $40.00 price objective on shares of Omnicell in a research note on Sunday, July 30th. Dougherty & Co increased their price objective on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Craig Hallum increased their price objective on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $51.57.
COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/19/191-88-million-in-sales-expected-for-omnicell-inc-omcl-this-quarter.html.
In other news, Chairman Randall A. Lipps sold 37,500 shares of the company’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $46.00, for a total value of $1,725,000.00. Following the completion of the transaction, the chairman now directly owns 196,551 shares of the company’s stock, valued at $9,041,346. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gary S. Petersmeyer sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $51.73, for a total value of $51,730.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 180,562 shares of company stock valued at $8,914,801. Company insiders own 3.77% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Omnicell by 2.3% in the second quarter. BlackRock Inc. now owns 4,589,119 shares of the company’s stock valued at $197,790,000 after acquiring an additional 101,776 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Omnicell by 3.7% in the second quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock valued at $83,105,000 after acquiring an additional 67,902 shares in the last quarter. Champlain Investment Partners LLC grew its holdings in shares of Omnicell by 6.2% in the first quarter. Champlain Investment Partners LLC now owns 1,698,140 shares of the company’s stock valued at $69,029,000 after acquiring an additional 99,075 shares in the last quarter. Conestoga Capital Advisors LLC grew its holdings in shares of Omnicell by 6.1% in the second quarter. Conestoga Capital Advisors LLC now owns 1,606,601 shares of the company’s stock valued at $69,245,000 after acquiring an additional 92,735 shares in the last quarter. Finally, Oak Ridge Investments LLC grew its holdings in shares of Omnicell by 0.6% in the second quarter. Oak Ridge Investments LLC now owns 1,537,940 shares of the company’s stock valued at $66,285,000 after acquiring an additional 8,491 shares in the last quarter. 96.35% of the stock is owned by institutional investors.
Omnicell (OMCL) traded down 0.978% on Tuesday, reaching $48.075. The company’s stock had a trading volume of 44,947 shares. The company’s market cap is $1.80 billion. Omnicell has a 52-week low of $30.35 and a 52-week high of $52.70. The firm’s 50-day moving average price is $50.08 and its 200 day moving average price is $43.57.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.